Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says

MT Newswires Live12-11

Sarepta Therapeutics's (SRPT) planned readout of data from its Myotonic Dystrophy Type 1 trial in fiscal Q1 2026 could boost investor sentiment about the company, Oppenheimer analysts said in a Wednesday note.

Analysts said that while Sarepta's Myotonic Dystrophy Type 1 program is two to three years behind its competitors, competitive safety and efficacy results could provide it with meaningful market share gains that are not currently priced into its stock.

Analysts said that the market is skeptical about the viability of the Duchenne muscular dystrophy medication Elevidys after several patient deaths.

Oppenheimer said that Sarepta's phosphorodiamidate morpholino oligomer, or PMO, therapy sales will not be impacted materially before 2028.

Analysts have an outperform rating on the stock and a $37 price target.

Price: 22.12, Change: -0.05, Percent Change: -0.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590531959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 01:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590531959","market":"nz","top_or_hot":-1,"title":"Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>'s (SRPT) planned readout of data from its Myotonic Dystrophy Type 1 trial in fiscal Q1 2026 could boost investor sentiment about the company, Oppenheimer analysts said in a Wednesday note.</p><p>Analysts said that while Sarepta's Myotonic Dystrophy Type 1 program is two to three years behind its competitors, competitive safety and efficacy results could provide it with meaningful market share gains that are not currently priced into its stock.</p><p>Analysts said that the market is skeptical about the viability of the Duchenne muscular dystrophy medication Elevidys after several patient deaths.</p><p>Oppenheimer said that Sarepta's phosphorodiamidate morpholino oligomer, or PMO, therapy sales will not be impacted materially before 2028.</p><p>Analysts have an outperform rating on the stock and a $37 price target.</p><p>Price: 22.12, Change: -0.05, Percent Change: -0.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-11 01:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>'s (SRPT) planned readout of data from its Myotonic Dystrophy Type 1 trial in fiscal Q1 2026 could boost investor sentiment about the company, Oppenheimer analysts said in a Wednesday note.</p><p>Analysts said that while Sarepta's Myotonic Dystrophy Type 1 program is two to three years behind its competitors, competitive safety and efficacy results could provide it with meaningful market share gains that are not currently priced into its stock.</p><p>Analysts said that the market is skeptical about the viability of the Duchenne muscular dystrophy medication Elevidys after several patient deaths.</p><p>Oppenheimer said that Sarepta's phosphorodiamidate morpholino oligomer, or PMO, therapy sales will not be impacted materially before 2028.</p><p>Analysts have an outperform rating on the stock and a $37 price target.</p><p>Price: 22.12, Change: -0.05, Percent Change: -0.23</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590531959","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590531959","pubTimestamp":1765386168,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sarepta Therapeutics's  planned readout of data from its Myotonic Dystrophy Type 1 trial in fiscal Q1 2026 could boost investor sentiment about the company, Oppenheimer analysts said in a Wednesday note.Analysts said that while Sarepta's Myotonic Dystrophy Type 1 program is two to three years behind its competitors, competitive safety and efficacy results could provide it with meaningful market share gains that are not currently priced into its stock.Analysts said that the market is skeptical about the viability of the Duchenne muscular dystrophy medication Elevidys after several patient deaths.Oppenheimer said that Sarepta's phosphorodiamidate morpholino oligomer, or PMO, therapy sales will not be impacted materially before 2028.Analysts have an outperform rating on the stock and a $37 price target.Price: 22.12, Change: -0.05, Percent Change: -0.23","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","OPY":"奥本海默控股","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4127":"投资银行业与经纪业","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"奥本海默表示，Sarepta Therapeutics的1型强直性肌营养不良试验数据可能会提振投资者情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1.5,"SRPT":1.5},"content_text":"Sarepta Therapeutics's (SRPT) planned readout of data from its Myotonic Dystrophy Type 1 trial in fiscal Q1 2026 could boost investor sentiment about the company, Oppenheimer analysts said in a Wednesday note.Analysts said that while Sarepta's Myotonic Dystrophy Type 1 program is two to three years behind its competitors, competitive safety and efficacy results could provide it with meaningful market share gains that are not currently priced into its stock.Analysts said that the market is skeptical about the viability of the Duchenne muscular dystrophy medication Elevidys after several patient deaths.Oppenheimer said that Sarepta's phosphorodiamidate morpholino oligomer, or PMO, therapy sales will not be impacted materially before 2028.Analysts have an outperform rating on the stock and a $37 price target.Price: 22.12, Change: -0.05, Percent Change: -0.23","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590531959","isCrawlerRequest":true}